ACGT October 2026 Research Roundup.
ACGT’s October Research Roundup invites you to our Lunch Symposium at SITC 2026, celebrates the Tang Prize awardees, and highlights early in vivo CAR T results in multiple myeloma and multiple sclerosis.
|
|
ACGT Lunch Symposium at SITC 2026
|
|
Join us in Phoenix on November 6
Heading to the SITC Annual Conference? Join the cancer cell and gene therapy community at the ACGT Lunch Symposium and enjoy an opportunity to reconnect during SITC and hear from leaders in the field.
Our keynote speaker, ACGT Research Fellow Renier Brentjens, MD, PhD (Roswell Park Comprehensive Cancer Center), will join ACGT Board of Directors member Marc Engelsgjerd, MD (Royalty Pharma), for a fireside chat. Brentjens, an early pioneer of CAR T cell therapy, recently shared his views on the field’s future with Gizmodo (see below).
We are also delighted to welcome ACGT Research Fellow Yvonne Chen, PhD (UCLA Health Jonsson Comprehensive Cancer Center), who will present her work, “Armored Chimeric Antigen Receptor T-cell Therapy Targets Antigen-Heterogeneous Glioma.”
When: Friday, November 6, 11:30 a.m.–1:30 p.m. local time
Where: Phoenix Convention Center, Room 124B, 100 N 3rd St, Phoenix, AZ 85004
Register now to save your seat.
|
|
ACGT Scientists in the News
|
|
- On September 18, Michel Sadelain, MD, PhD (Columbia University), Carl H. June, MD (University of Pennsylvania), and Steven A. Rosenberg, MD, PhD (National Cancer Institute) were honored with the 2026 Tang Prize in Biopharmaceutical Science at a ceremony in Taipei, Taiwan, “for the discovery and development of tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor T-cell (CAR-T) therapies.” The prize was covered by Columbia University, Taipei Times, Focus Taiwan, and GeneOnline (forum recap; laureates overview), among others.
- Maciej S. Lesniak, MD (Northwestern University), Alexander Marson, MD, PhD (Gladstone-UCSF Institute of Genomic Immunology), and Katy Rezvani, MD, PhD (The University of Texas MD Anderson Cancer Center) were elected to the National Academy of Medicine, one of the highest honors in health and medicine.
- Christine E. Brown, PhD (City of Hope) was named to the Forbes 2026 50 Over 50: Innovation list. Forbes highlighted her work bringing CAR T cell therapy to patients with glioblastoma, noting that her early trials helped show that CAR T cells can be safely delivered to the brain and that she now leads four ongoing glioblastoma trials. Brown and colleagues also shared specialized “plug and play” CAR T cells with a molecular docking site, so researchers can attach add-ons after infusion to track the cells, support their growth, and recognize a broader range of cancer cells. The research study was published in Cancer Immunology Research, and covered by BioSpace.
- Stephen Gottschalk, MD (St. Jude Children’s Research Hospital) received an All-Star Grant, which provides $1 million over five years, from the V Foundation for Cancer Research’s Dick Vitale Pediatric Cancer Research Fund. The fund awarded $16.2 million in total to researchers at 17 cancer centers.
- Carl H. June, MD (UPenn) was featured in an OncoDaily piece that declared his work with genetically engineered CAR T cells deserving of Nobel Prize recognition. A USA Today story highlighted June and the concept of pursuing long-shot “three-pointer” ideas, tracing his decades of progress in cell and gene therapy. In addition, BioBuzz reported that B+ Labs, the Philadelphia life sciences incubator that is home to June’s company BlueWhale Bio, was named a 2026 FIRE Awards honoree by PHL Inno, the Philadelphia Business Journal’s innovation section.
- Medici Therapeutics, where Ira Mellman, PhD (Parker Institute for Cancer Immunotherapy) is a co-founder and the chief scientific officer, was named a 2026 Endpoints 11 winner by Endpoints News. Medici is developing a vaccine-reinforced cell therapy.
- Link Cell Therapies, co-founded by Crystal L. Mackall, MD (Stanford University), raised $30 million in an expanded Series A, bringing the round to $90 million for the company developing logic-gated CAR T cell therapies for solid tumors and blood cancers. MedPath also covered this news.
- Cellinfinity Bio, the cell therapy company founded by Sidi Chen, PhD (Yale University), won first prize in the 2026 AIM-HI BRACE Award Venture Competition, which Chen accepted at the National Foundation for Cancer Research (NFCR) Global Summit on October 9 in Washington, DC. Chen was also highlighted in a Yale School of Medicine article on efforts to make CAR T cell therapy more effective and safer, and to extend it from cancer to autoimmune diseases.
- Carl H. June, MD (UPenn), Ira Mellman, PhD (PICI and Medici), and Crystal Mackall, MD (Stanford University) all took the virtual stage at OncoDaily’s IMMUNO 2026 congress. June discussed the road to solid tumors for CAR T cells; Mellman delivered a lecture titled “The Cancer Immunity Cycle and the Next Scientific Frontiers”; and Mackall presented her team’s work on CAR T cells for diffuse midline glioma, as well as a new engineering approach that uses a natural protease cut site to help CAR T cells dial back excessive stimulation.
- Renier Brentjens, MD, PhD (Roswell Park Comprehensive Cancer Center) spoke with Gizmodo about the future of CAR T-cell therapy. (Here is our recent interview with Brentjens.)
- Philip D. Greenberg, MD (Fred Hutchinson Cancer Center) was hailed as “The Pioneer” in a Fred Hutch series profiling the people behind the center’s breakthroughs.
- Robert H. Vonderheide, MD, DPhil (University of Pennsylvania) was quoted in The New York Times on new results for intismeran, a personalized mRNA cancer vaccine that, in a late-stage trial of more than 1,100 people with high-risk melanoma that had been surgically removed, was found to cut the risk recurrence by 42% at two years when added to the PD-1 checkpoint immunotherapy pembrolizumab (Keytruda).
- Brian D. Brown, PhD (Icahn School of Medicine at Mount Sinai) and colleagues drew coverage from SciTechDaily and Medical Xpress for their study published in Nature showing that rare pancreatic cancer cells can shield surrounding tumor cells from immune attack.
- Sheila K. Singh, MD, PhD (King’s College London) delivered her inaugural lecture as Richard Dimbleby Professor of Cancer Research at King’s College London on October 7, titled “The evolution of brain tumour initiating cells: Chasing a moving target.”
- Hideho Okada, MD, PhD (University of California, San Francisco) was awarded an honorary doctorate by Uppsala University’s Faculty of Medicine in Sweden, for his more than three decades of translational immunotherapy work for brain tumors, including his discovery of cytotoxic T lymphocyte epitopes in glioma-associated antigens.
- Sidi Chen, PhD (Yale University) was highlighted in a Yale School of Medicine article on efforts to make CAR T cell therapy more effective and safer, and to extend it from cancer to autoimmune diseases.
|
|
ACGT Scientist Research Impact
|
|
- Christine E. Brown, PhD (City of Hope) and colleagues argued that patient-derived organoids, which retain key features of human tumors such as their mix of cell types and tissue structure, can help fill a gap left by preclinical models that do not fully reflect human tumor biology. This article was published in Cancer Cell.
- A team including E. Antonio Chiocca, MD, PhD (Brigham and Women’s Hospital) described how IDH mutations may make high-grade astrocytomas, a type of brain tumor, more susceptible to oncolytic virotherapy with HSV-1. This ACGT-funded work was published in Molecular Therapy Oncology.
- A team including Stephen Gottschalk, MD (St. Jude Children’s Research Hospital) engineered “metabolically rewired” CAR T cells that co-express ADA1, an enzyme that breaks down the immunosuppressive metabolite adenosine, and CD26, a protein linked to T cell migration. This research was published in Biomedicines.
- A team including Stephan A. Grupp, MD, PhD (Children’s Hospital of Philadelphia) and Marcela V. Maus, MD, PhD (Mass General Brigham Cancer Institute) updated the American Society for Transplantation and Cellular Therapy (ASTCT) consensus criteria for grading toxicities after immune effector cell therapies such as CAR T cells. This consensus statement was published in Transplantation and Cellular Therapy.
- Michael Z. Lin, MD, PhD (Stanford University) and colleagues developed a way to switch on gene editing in specific parts of the body without surgery or injections at the target site. This research was published in Cell.
- Crystal L. Mackall, MD (Stanford University) and Diren Usta, MD, reviewed the state of CAR T-cell therapy, which now includes seven FDA-approved products across 15 indications and more than 2,600 active clinical trials. In addition, a team including Mackall developed DESynR, an approach that builds synthetic transcription factors by recombining domains from a single protein family. These articles were published in Cancer Cell and Cell, respectively.
- Douglas Mahoney, PhD (University of Calgary) and colleagues found that oncolytic viruses delivered through the bloodstream rarely infected cancer cells in mouse tumor models, but consistently infected the pericyte cells that surround blood vessels. This research was published in Molecular Medicine.
- Marcela V. Maus, MD, PhD (Mass General Brigham Cancer Institute) and colleagues investigated why cilta-cel has outperformed ide-cel, two BCMA-targeted CAR T cell therapies for multiple myeloma. This research was published in the Journal for ImmunoTherapy of Cancer.
- Hideho Okada, MD, PhD (University of California, San Francisco) and colleagues reviewed what is known about brain-resident memory T cells, a long-lived population of immune cells that remain in the brain. This review was published in Cellular and Molecular Bioengineering.
- Sheila K. Singh, MD, PhD (King’s College London) and colleagues used genome-wide CRISPR screens in patient-derived glioblastoma stem cell models to identify FEN1, a DNA replication and repair enzyme, as essential for these cells’ survival, especially under temozolomide chemotherapy. This research was published in Cancer Research Communications.
- Robert H. Vonderheide, MD, DPhil (University of Pennsylvania) and Nune Markosyan, PhD, reviewed progress in personalized cancer vaccines, which target neoantigens arising from the mutations in a patient’s own tumor. This review was published in Nature Communications.
|
|
Industry and Clinical Updates
|
|
- Personalized mRNA cancer vaccine cuts melanoma recurrence in phase 3 trial. Merck and Moderna announced that adding intismeran autogene, an mRNA-based individualized neoantigen therapy, to Keytruda reduced the risk of recurrence or death by 42% versus Keytruda alone in 1,137 patients with surgically removed stage IIB–IV melanoma. At two years, 82.2% of patients receiving the combination remained recurrence-free, compared with 70.0% with Keytruda alone. The results were presented at ESMO 2026 and accepted for publication in the New England Journal of Medicine.
- In vivo CAR T therapy shows striking early results in multiple myeloma. At the International Myeloma Society meeting on September 26, IASO Bio reported first-in-human results for IASO206, a single infusion that generates BCMA-targeted CAR T cells inside the body. It requires no lab manufacturing and no lymphodepleting chemotherapy. Among the first 10 patients, 90% responded and 90% had no detectable residual disease. The trial evaluated three dose levels, and all patients treated at the highest dose responded. Ten days earlier, the FDA cleared the company’s second in vivo CAR T, IASO208, for a U.S. lymphoma trial.
- FDA launches pilot to speed first-in-human trials. On September 15, the FDA opened applications for its Expedited IND Pilot, which pairs drug developers with qualified research institutions to shorten the path to first-in-human trials. The FDA expects to initially select 8 to 10 developer and institution pairs. Applications are due October 30.
- Why off-the-shelf CAR T cells work in some patients but not others. An MD Anderson study published September 25 in Cancer Discovery examined donor-derived CAR T cells in patients with large B-cell lymphoma. Some patients’ immune systems rejected the cells before they could expand. The team also identified CAR T cell populations that were better equipped to multiply and persist. This points to better donor selection and manufacturing for off-the-shelf products.
- Gut bacteria may help or hinder CAR T-cell therapy. A new study in Cell found that metabolites produced by gut microbes can either boost or suppress CAR T-cell function, with a major effect on outcomes. A metabolite-based risk score predicted which patients would respond.
- In vivo CAR T shows early promise in multiple sclerosis. A small early-stage study reported in the New England Journal of Medicine tested JY231, an “off-the-shelf” lentiviral vector administered via a single intravenous infusion to directly engineer the patient’s CD19-targeted CAR T cells inside their body. It was associated with less disability and improved motor and cognitive function in seven patients with neurologic autoimmune disease who participated in the clinical trial.
- Roswell Park launches a trial of “armored” CAR T cells for ovarian cancer. On October 1, Roswell Park Comprehensive Cancer Center treated the first patient in a phase 1 trial of GB-5267, a CAR T-cell therapy developed with Generate Biomedicines. The therapy targets MUC16, which is overexpressed in more than 80% of ovarian tumors, and is armored with the cytokine IL-18 to help the cells withstand the tumor’s suppressive environment. The cells are delivered both intravenously and into the abdominal cavity, where ovarian cancer spreads, and the trial does not require lymphodepleting chemotherapy. It is enrolling patients whose cancer has returned or is resistant to platinum chemotherapy.
|
|
|